Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Industry

Regeneron Ireland Profits Rise 20% to $4.91bn in 2025

Sreepriya Prasannan
Sreepriya Prasannan

NewsWritten by our team from the primary sources linked below. Reviewed, verified and approved by a human editor. How we check

Speed:
Regeneron Ireland Profits Rise 20% to $4.91bn in 2025

Pretax profit at Regeneron Ireland DAC, the Irish arm of US biotech Regeneron, rose 20% to $4.91bn in 2025, according to accounts filed with the Companies Registration Office, as reported by The Irish Times and the Irish Examiner. Revenue rose 3% to $12.53bn and headcount grew to 2,163, most of them in Limerick.

The accounts also record $5.3bn in dividends paid to the parent group in 2025 and a brief interruption to Limerick bulk manufacturing in early 2026, caused by unplanned facility repairs.

Key Highlights:
  • Profit: pretax profit up 20% to $4.91bn in 2025; profit after tax of $4.19bn.
  • Revenue: up 3% from $12.15bn to $12.53bn, which the Irish Examiner puts at 87.6% of Regeneron's 2025 global revenue of $14.3bn.
  • Tax: corporation tax charge of $716.6m, of which $120m came from the Pillar Two global minimum tax rules.
  • Jobs: headcount rose from 2,082 to 2,163, with 1,956 people in production.
  • Limerick: bulk manufacturing was "temporarily interrupted" by facility repairs that began in the first quarter of 2026; production recommenced by June 2026.

What do the Regeneron Ireland accounts show?

Regeneron Ireland DAC is the Irish operating company of Regeneron Pharmaceuticals, the New York biotech behind the eye medicine Eylea (aflibercept) and, with Sanofi, the eczema and asthma medicine Dupixent (dupilumab). Its 2025 accounts show pretax profit up 20% to $4.91bn. After a corporation tax charge of $716.6m, profit after tax was $4.19bn. All figures are in US dollars.

Revenue rose by 3%, from $12.15bn to $12.53bn. The Irish Examiner reports that $8.14bn of this came from collaboration revenues and $4.19bn from intercompany revenues. On that basis, the Irish company accounted for 87.6% of Regeneron's global revenue of $14.3bn in 2025.

The profit figure was reached after non-cash amortisation costs of $676.2m and depreciation of $92.4m. Spending on research and development came to $1.09bn.

Regeneron Ireland DAC: key figures for 2025 (accounts filed with the CRO, as reported by The Irish Times and the Irish Examiner)
Measure2025 (2024 where reported)
Revenue$12.53bn (2024: $12.15bn), up 3%
Pretax profit$4.91bn, up 20%
Corporation tax charge$716.6m, including $120m from Pillar Two
Profit after tax$4.19bn
Research and development spend$1.09bn
Dividends paid to parent$5.3bn in 2025, plus $1.5bn in March 2026
Employees2,163 (2024: 2,082)
Staff costs$349.5m, including share-based payments of $64.4m
Directors' pay (five directors)$1.88m (2024: $1.66m)
Shareholder funds$6.19bn, including accumulated profits of $1.9bn

How much corporation tax did Regeneron Ireland pay?

The corporation tax charge for 2025 was $716.6m. The accounts state that the Pillar Two reforms added $120m to the company's Irish corporation tax. Pillar Two is the OECD-agreed global minimum tax of 15% for large multinational groups. The extra $120m is the cost of those rules to the Irish company in 2025.

Where did the profits go?

The company paid dividends of $5.3bn in 2025 to its parent, Regeneron International Holdings LLC. A further dividend of $1.5bn followed in March 2026. Even after these payments, shareholder funds stood at $6.19bn at the end of 2025, including accumulated profits of $1.9bn.

What happened at the Limerick plant in 2026?

The accounts say bulk manufacturing in Limerick "was temporarily interrupted due to unanticipated facility repairs that commenced during the first quarter of 2026". Both newspapers report that production had recommenced by June 2026.

Regeneron's third-quarter 2026 results release, published on 30 October 2026, does not mention Limerick by name. It does list "temporary manufacturing interruption-related costs" of $161.3m in cost of goods sold and $14.8m in cost of collaboration manufacturing for the first nine months of 2026, with no such costs recorded in the third quarter itself. The release does not say which facility they relate to.

How many people does Regeneron employ in Ireland?

Headcount at Regeneron Ireland DAC rose from 2,082 to 2,163 during 2025. Of these, 1,956 worked in production, 75 in research and development, 118 in administration and 14 in commercial roles. Staff costs were $349.5m, including share-based payments of $64.4m. Pay for the five directors rose from $1.66m to $1.88m. Most staff are based at the Limerick plant, with the rest in Dublin.

The Limerick campus sits at Raheen, on the site of the former Dell computer factory. Regeneron first announced the project in December 2013, with a plan for $300m of investment and 300 jobs. In October 2015 it added $350m and 200 jobs, taking planned investment to $650m by the end of 2017, according to the Department of Enterprise. In August 2020 RTÉ reported 400 more jobs at Raheen, which it described as the largest bulk biologics production facility in the country, and said Regeneron had invested more than $1bn in the campus by then. You can follow the company on our Regeneron Ireland page.

Frequently asked questions

What is Regeneron Ireland DAC?

It is the Irish subsidiary of Regeneron Pharmaceuticals. It runs the company's large biologics manufacturing campus in Raheen, Limerick, and has staff in Dublin.

How much profit did Regeneron Ireland make in 2025?

Pretax profit was $4.91bn, up 20%. After a tax charge of $716.6m, profit after tax was $4.19bn.

Why was Limerick production interrupted?

The accounts cite "unanticipated facility repairs" that began in the first quarter of 2026. Production had restarted by June 2026.

What medicines is Regeneron known for?

Its best-known products include Eylea and Eylea HD (aflibercept) for eye disease and Dupixent (dupilumab), developed with Sanofi.

Outlook

The Irish company now carries most of Regeneron's global revenue, so the Limerick plant matters to the whole group. The next set of Irish accounts, covering 2026, should show how far the repair work affected output and costs at Limerick. Regeneron has not said publicly which site the interruption costs in its quarterly release relate to. Priya Life Science will report on any new investment or jobs announcement for the Raheen campus.

Sources

Cover image: AI-generated illustration. It is not a photograph of Regeneron's Limerick site.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Related from our data
Dupixent 200 mg solution for injection in pre-filled pen — Dupilumab · Irish Medicines Database
Drugs in this article: current clinical trials
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: a 60-second summary, then only the topics you choose: industry news, approvals and market access, shortages, Irish trials, careers or data, all built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · Industry

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment